A new U.S. study found Anoro Elipta to be better than Bevespi Aerosphere or Stiolto Respimat at lowering the risk of disease flares in COPD.
Anoro Ellipta is meant to be used as a long-term treatment for COPD. If you and your doctor determine that Anoro is safe and effective for you, you’ll likely take it long term.
BioWorld - Tuesday, November 21, 2023 See today's BioWorld Home » Anoro Ellipta Briefing Docs Promising Ahead of PADAC Meeting Subscribe to BioWorld™ news services See subscription options To read the ...
The U.S. Food and Drug Administration have approved GlaxoSmithKline’s Anoro™ Ellipta™, the company announced. The product is used to treat chronic obstructive ...
WASHINGTON, Sept 10 (Reuters) - A federal advisory panel recommended approval of GlaxoSmithKline Plc's new drug to treat chronic obstructive pulmonary disease(COPD ...
The FINANCIAL — GlaxoSmithKline plc (GSK) and Theravance, Inc. on September 27 announced data presented by GSK at the European Respiratory Society (ERS) International Congress (poster PA1001), from an ...
Novel drug effective for asthma, COPD Reviewers are questioning the safety profile of combination umeclidinium/vilanterol after noting inconsistencies in data from ...
Panelists on the FDA’s Pulmonary-Allergy Drugs Advisory Committee that convened to decide about Anoro Ellipta, the inhaler product for chronic obstructive pulmonary disease (COPD), proved harder to ...
Please provide your email address to receive an email when new articles are posted on . Outcomes may vary among different fixed-dose combination inhalers for COPD ...
Umeclidinium 62.5mcg, vilanterol 25mcg; per inhalation; dry pwd for oral inhalation. LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results